Hisamitsu Pharmaceutical Co
4530.T
Filed as Hisamitsu Pharmaceutical Co.,Inc. (2022-07–2025-10)
Financials · Consolidated
| Fiscal year ended | 2025-02 | 2024-02 | 2023-02 | 2022-02 | 2021-02 | 2020-02 |
|---|---|---|---|---|---|---|
| Revenue | ¥156.0bn | ¥141.7bn | ¥128.3bn | ¥120.2bn | ¥114.5bn | ¥141.0bn |
| Operating income | ¥18.9bn | ¥13.2bn | ¥11.6bn | ¥9.3bn | — | — |
| Ordinary income | ¥24.0bn | ¥19.6bn | ¥16.1bn | ¥12.6bn | ¥11.8bn | ¥25.6bn |
| Net income (owners) | ¥21.8bn | ¥14.0bn | ¥11.7bn | ¥9.7bn | ¥9.3bn | ¥18.7bn |
| Total assets | ¥343.1bn | ¥328.8bn | ¥313.9bn | ¥302.9bn | ¥299.9bn | ¥307.4bn |
| Net assets / equity | ¥279.4bn | ¥267.1bn | ¥258.4bn | ¥254.9bn | ¥253.8bn | ¥250.7bn |
| Operating cash flow | ¥18.8bn | ¥18.2bn | ¥12.7bn | ¥19.2bn | ¥5.3bn | ¥27.4bn |
| EPS (basic) | ¥295.57 | ¥181.62 | ¥148.01 | ¥118.92 | ¥113.22 | ¥227.58 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 4
| Period | Form | Figures |
|---|---|---|
| 2023-03-01 → 2023-11-30 | Quarterly Q3 | 48 figures · EDINET |
| 2023-03-01 → 2023-08-31 | Quarterly Q2 | 72 figures · EDINET |
| 2023-03-01 → 2023-05-31 | Quarterly Q1 | 46 figures · EDINET |
| 2022-03-01 → 2023-02-28 | Annual | 206 figures · EDINET |
22 more reports are still being processed.